Small molecule therapeutic developer Morphic, based on research at Harvard Medical School, has boosted its initial public offering from $90m to nearly $104m.
US-based integrin drug developer Morphic Holding, which emerged out of research at Harvard University’s Medical School, closed its initial public offering at approximately $104m yesterday.
The company had floated on the Nasdaq Global Market in a $90m IPO last week, pricing 6 million shares at $15.00 each. The shares closed at $18.00 on their first day of trading and were $22.67 by the close of trading yesterday.
Joint bookrunning managers Jefferies, Cowen and Company, BMO Capital Markets…
